Second-generation antihistamines: a study of poisoning in children

References

• Kuna P, Jurkiewicz D, Czarnecka-Operacz MM, et al. The role and choice criteria of antihistamines in allergy management – expert opinion. Postepy Dermatol Alergol. 2016; 6:397–410.
   Google Scholar
• Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2018;73:1393–1414.
   PubMed Web of Science ®Google Scholar
• Brożek JL, Bousquet J, Agache I, et al. Allergic rhinitis and its impact on asthma (ARIA) guidelines-2016 revision. J Allergy Clin Immunol. 2017;140:950–958.
   PubMed Web of Science ®Google Scholar
• Asher MI, Montefort S, Björkstén B, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC phases one and three repeat multicountry cross-sectional surveys. Lancet. 2006;368:733–743.
   PubMed Web of Science ®Google Scholar
• Ghouri N, Hippisley-Cox J, Newton J, et al. Trends in the epidemiology and prescribing of medication for allergic rhinitis in England. J R Soc Med. 2008;101:466–472.
   PubMed Web of Science ®Google Scholar
• Simons FE, Simons KJ. Histamine and H1-antihistamines: celebrating a century of progress. J Allergy Clin Immunol. 2011;128:1139–1150.
   PubMed Web of Science ®Google Scholar
• HAS Haute Autorité de Santé [Internet]. Saint-Denis La Plaine (France): HAS; 2005 [cited 2018 Feb 15]. Available from: https://www.has-sante.fr/portail/upload/docs/application/pdf/ct032248.pdf
   Google Scholar
• Dumoulin M, Martin K, Titier K, et al. Cardiotoxicity of second generation antihistamines. Revue Française D’allergologie et D’immunologie Clinique. 2006;46:392–401.
   Web of Science ®Google Scholar
• Luscombe MD, Owens BD, Burke D. Weight estimation in paediatrics: a comparison of the APLS formula and the formula 'Weight = 3(age)+7' . Emerg Med J. 2011;28:590–593.
   PubMed Web of Science ®Google Scholar
• Persson HE, Sjöberg GK, Haines JA, et al. Poisoning severity score. Grading of acute poisoning. J Toxicol Clin Toxicol. 1998;36:205–213.
   PubMed Web of Science ®Google Scholar
• Prenner B, Ballona R, Bueso A, et al. Safety of desloratadine syrup in children six months to younger than 2 years of age: a randomized, double-blinded, placebo-controlled study. Pediatr Asthma Allergy Immunol. 2006;19:91–99.
   Google Scholar
• Bloom M, Staudinger H, Herron J. Safety of desloratadine syrup in children. Curr Med Res Opin. 2004;20:1959–1965.
   PubMed Web of Science ®Google Scholar
• Potter P, Mitha E, Barkai L, et al. Rupatadine is effective and safe in the treatment of chronic spontaneous urticaria (CSU) in pediatric patients (2-11 years old). Clin Transl Allergy. 2014;4:O10.
   PubMedGoogle Scholar
• Simons FE, Watson WT, Simons KJ. Pharmacokinetics and pharmacodynamics of ebastine in children. J Pediatr. 1993;122:641–646.
   PubMed Web of Science ®Google Scholar
• Boner AL, Miglioranzi P, Richelli C, et al. Efficacy and safety of loratadine suspension in the treatment of children with allergic rhinitis. Allergy. 1989;44:437–441.
   PubMed Web of Science ®Google Scholar
• Anuradha P, Maiti R, Jyothirmai J, et al. Loratadine versus levocetirizine in chronic idiopathic urticaria: a comparative study of efficacy and safety. Indian J Pharmacol. 2010;42:12–16.
   PubMed Web of Science ®Google Scholar
• Salmun LM, Herron JM, Banfield C, et al. The pharmacokinetics, electrocardiographic effects, and tolerability of loratadine syrup in children aged 2 to 5 Years. Clin Ther. 2000;22:613–621.
   PubMed Web of Science ®Google Scholar
• Milgrom H, Kittner B, Lanier R, et al. Safety and tolerability of fexofenadine for the treatment of allergic rhinitis in children 2 to 5 years old. Ann Allergy Asthma Immunol. 2007;99:358–363.
   PubMed Web of Science ®Google Scholar
• de Blic J, Wahn U, Billard E, et al. Levocetirizine in children: evidenced efficacy and safety in a 6-week randomized seasonal allergic rhinitis trial. Pediatr Allergy Immunol. 2005;16:267–275.
   PubMed Web of Science ®Google Scholar
• Davies BH, Mullins J, Couch HA. Prophylactic treatment of seasonal allergic rhinitis: a comparaison of cetirizine (Zirtek) and terfenadine (Triludan. ). Clin Trials J. 1989;26:100–107.
   Google Scholar
• Ridout SM, Tariq SM. Cetirizine overdose in a young child. J Allergy Clin Immunol. 1997;99:860–861.
   PubMed Web of Science ®Google Scholar
• Hansen JJ, Feilberg Jorgensen NH. Accidental cetirizine poisoning in a four year old boy. Ugeskr Laeger. 1998;160:5946–5947.
   PubMedGoogle Scholar
• Cobb DB, Watson WA, Fernandez MC. High-dose loratadine exposure in a six-year-old child. Vet Hum Toxicol. 2001;43:163–164.
   PubMedGoogle Scholar
• Sanguinetti MC. Na + 1-activated and ATP-sensitive K + channels in the heart. Prog Clin Biol Res. 1990;334:85–109.
   PubMedGoogle Scholar
• Woosley RL, Chen Y, Freiman JP, et al. Mechanism of the cardiotoxic actions of terfenadine. JAMA.1993;269:1532–1536.
   PubMed Web of Science ®Google Scholar
• Salata JJ, Jurkiewicz NK, Wallace AA, et al. Cardiac electrophysiological actions of the histamine H1-receptor antagonists astemizole and terfenadine compared with chlorpheniramine and pyrilamine. Circ Res. 1995;76:110–119.
   PubMed Web of Science ®Google Scholar
• Yap YG, Camm AJ. The current cardiac safety situation with antihistamines. Clin Exp Allergy. 1999;29: 15–24.
   PubMed Web of Science ®Google Scholar
• Taglialatela M, Pannaccione A, Castaldo P, et al. Inhibition of HERG1 K(+) channels by the novel second-generation antihistamine mizolastine. Br J Pharmacol. 2000;131:1081–1088.
   PubMed Web of Science ®Google Scholar
• Moss AJ, Chaikin P, Garcia JD, et al. A review of the cardiac systemic side-effects of antihistamines: ebastine. Clin Exp Allergy. 1999;29:200–205.
   PubMed Web of Science ®Google Scholar
• Ohtani H, Hanada E, Hirota M, et al. Inhibitory effects of the antihistamines epinastine, terfenadine, and ebastine on potassium currents in rat ventricular myocytes. J Pharm Pharmacol. 1999;51:1059–1063.
   PubMed Web of Science ®Google Scholar
• Meeves SG, Appajosyula S. Efficacy and safety profile of fexofenadine HCl: a unique therapeutic option in H1-receptor antagonist treatment. J Allergy Clin Immunol. 2003;112:69–77.
   PubMedGoogle Scholar
• Berger WE. The safety and efficacy of desloratadine for the management of allergic disease. Drug Saf. 2005;28:1101–1118.
   PubMed Web of Science ®Google Scholar
• Yap YG, Camm AJ. Potential cardiac toxicity of H1-antihistamines. Clin Allergy Immunol. 2002;17:389–419.
   PubMedGoogle Scholar
• Hey JA, del Prado M, Kreutner W, et al. Cardiotoxic and drug interaction profile of the second generation antihistamines ebastine and terfenadine in an experimental animal model of torsade de pointes. Arzneimittelforschung. 1996;46:159–163.
   PubMed Web of Science ®Google Scholar
• Ten Eick AP, Blumer JL, Reed MD. Safety of antihistamines in children. Drug Saf. 2001;24:119–147.
   PubMed Web of Science ®Google Scholar
• Nine JS, Rund CR. Fatality from diphenhydramine monointoxication: a case report and review of the infant, pediatric, and adult literature. Am J Forensic Med Pathol. 2006;27:36–41.
   PubMed Web of Science ®Google Scholar
• Baker AM, Johnson DG, Levisky JA, et al. Fatal diphenhydramine intoxication in infants. J Forensic Sci 2003;48:425–428.
   PubMed Web of Science ®Google Scholar
• Marinetti L, Lehman L, Casto B, et al. Over-the-counter cold medications-postmortem findings in infants and the relationship to cause of death. J Anal Toxicol. 2005;29:738–743.
   PubMed Web of Science ®Google Scholar
• Wingert WE, Mundy LA, Collins GL, et al. Possible role of pseudoephedrine and other over-the-counter cold medications in the deaths of very young children. J Forensic Sci. 2007;52:487–490.
   PubMed Web of Science ®Google Scholar
• Eckes L, Tsokos M, Herre S, et al. Pots-mortem evidence of doxylamine in toxicological analyses. Sci Justice. 2014;54:61–65.
   PubMed Web of Science ®Google Scholar
• Radovanovic D, Meier PJ, Guiguis M, et al. Dose-dependent toxicity of diphenhydramine overdose. Hum Exp Toxicol 2000;19:489–495.
   PubMed Web of Science ®Google Scholar
• Yanai K, Rogala B, Chugh K, et al. Safety considerations in the management of allergic diseases: focus on antihistamines. Curr Med Res Opin. 2012;28:623–642.
   PubMed Web of Science ®Google Scholar
• Church MK, Maurer M, Simons FE, et al. Risk of first-generation H(1)-antihistamines: a GA(2)LEN position paper. Allergy. 2010;65:459–466.
   PubMed Web of Science ®Google Scholar
• Vuurman EF, van Veggel LM, Uiterwijk MM, et al. Seasonal allergic rhinitis and antihistamine effects on children’s learning. Ann Allergy. 1993;71:121–126.
   PubMedGoogle Scholar
• Vuurman EF, van Veggel LM, Sanders RL, et al. Effects of semprex-D and diphenhydramine on learning in young adults with seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 1996;76:247–252.
   PubMed Web of Science ®Google Scholar
• Scadding G. Optimal management of nasal congestion caused by allergic rhinitis in children: safety and efficacy of medical treatments. Paediatr Drugs. 2008;10:151–162.
   PubMedGoogle Scholar